Sionna chooses Phase 2a cystic fibrosis drug after healthy volunteer study
Newly-public biotech Sionna Therapeutics is ready to head into mid-stage testing. In an update reporting healthy volunteer data for two cystic fibrosis drugs, Sionna said it will move SION-719 into a...
View ArticleExclusive: CinDome gets another $40M to advance gastroparesis drug
CinDome Pharma collected an additional $40 million from existing investors to run another Phase 2 study of its gastroparesis drug, CinRx CEO Jon Isaacsohn exclusively told Endpoints News. It's been...
View ArticleStruggling biotechs succumb to icy market, as money dries up and clinical...
In the span of 15 days, the fate of iTeos Therapeutics soured quickly. Once a beacon of the anti-TIGIT class, the company this spring faced two major issues: a key clinical failure for its cancer ...
View ArticleVigil drug fails a Phase 2; Merus aims to raise $300M
Plus, news about Bayer: Vigil Neuroscience's Phase 2 fail: The neurodegenerative disease biotech stopped a long-term extension trial of iluzanebart for a rare disease called adult-onset...
View ArticleAnaptysBio describes ‘JAK-like’ efficacy for PD-1 drug in rheumatoid arthritis
AnaptysBio is claiming success with longer follow-up data from a Phase 2b trial in rheumatoid arthritis as it looks for a partner to take its PD-1 drug into Phase 3. Back in February, the company ...
View ArticleSagimet touts China partner Ascletis' Phase 3 FASN inhibitor data in acne
Sagimet Biosciences' FASN inhibitor denifanstat succeeded in a China-based Phase 3 trial in moderate-to-severe acne that was run by its local partner Ascletis. While that trial is for the Chinese...
View ArticleEx-HHS workers accuse Kennedy of relying on flawed data to issue firings
The Trump administration is being accused of relying on faulty personnel data to fire 10,000 employees from federal health agencies, according to a proposed class action brought by seven laid-off...
View ArticleAfter layoffs, Casma eyes path to clinic with autophagy-boosting drug
Casma Therapeutics is unveiling its first preclinical data suggesting that a novel drug can enhance the ability of brain cells to clear out molecular garbage, an approach that it hopes will lead to new...
View ArticleSarepta’s gene therapy vector wins FDA platform technology status
Sarepta Therapeutics said Wednesday it won “platform technology” status for one of its gene therapy components, marking the first public disclosure from a company to receive the long-awaited FDA...
View ArticleDigital health startup Virta stakes fees on curbing GLP-1 prescriptions
In a move to put its money where its mouth is, digital health startup Virta Health said it’s now guaranteeing employers they won’t see increased GLP-1 weight loss prescriptions, or they'll get their...
View ArticleAmplify raises $200M biotech fund, hires Elliot Hershberg as partner
Over its 13-year history, Amplify Partners has dabbled in the life sciences as an early backer in companies like Recursion Pharmaceuticals and PicnicHealth. Now, the Menlo Park, CA-based VC firm is...
View ArticleExclusive: Allay reaches $57.5M Series D milestone for Phase 2b pain trial
NEW YORK — Allay Therapeutics has corralled $57.5 million in a Series D to help it complete a Phase 2b pain trial and gear up for a Phase 3 next summer, the biotech exclusively told ...
View ArticleRestarted auction for 23andMe comes with $305M offer from former CEO Anne...
Anne Wojcicki, the former CEO of beleaguered genetics testing service 23andMe, isn’t giving up her fight to take back the company she started in her sister's garage in 1998. Wojcicki is making a $305...
View ArticleStartup General Medicine wants to change online shopping for healthcare
General Medicine wants to make getting healthcare as easy as online shopping. The startup, launched by former Amazon employees who raised $32 million in funding late May, runs an online healthcare...
View ArticleRegenxbio reports Duchenne gene therapy data from five patients
Regenxbio announced the latest functional outcomes of five children with Duchenne muscular dystrophy who received its gene therapy. The muscle disease biotech said on Thursday that all five patients...
View ArticleCullinan's deal for T cell engager from China; Kardigan buys late-stage heart...
Plus, news about Novartis, Signify Bio, Ocugen, Dynavax and ViGeneron: Cullinan Therapeutics gets rights to T cell engager developed in China: The company made a deal with Chongqing-based Genrix Bio...
View ArticleFDA's Prasad details decision to pause chikungunya vaccine in seniors
The FDA and CDC's decision last month to pause administering Valneva's live-attenuated chikungunya vaccine in patients 60 and older was meant to provide more time to examine a potential causal...
View ArticleCorcept plots future for ALS drug that flunked Phase 2, citing survival analysis
Corcept Therapeutics is piecing together a path forward for an experimental drug that failed a mid-stage ALS study after new data showed the treatment boosted survival outcomes. Back in December, the...
View ArticleSchott Pharma's €100M+ Hungary expansion; Antheia’s $56M Series C raise
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Schott Pharma is investing over €100 million ($114 million) to expand...
View ArticleGenerics giant Teva turns to branded drugs R&D for its future
NEW YORK — A decade ago, Teva Pharmaceutical nearly sank its century-old business when it struck a $40.5 billion deal. In July 2015, Teva announced it would buy Allergan's generics business ...
View Article